https://openbell.ai/ 2026-10-19T11:34:37.711Z hourly 1.0 https://openbell.ai/support 2026-10-19T11:34:37.711Z monthly 0.7 https://openbell.ai/privacy 2026-10-19T11:34:37.711Z monthly 0.5 https://openbell.ai/terms 2026-10-19T11:34:37.711Z monthly 0.5 https://openbell.ai/feed.json 2026-10-19T11:34:37.711Z hourly 0.8 https://openbell.ai/news/BWAY:1792409660269 2026-10-19T11:34:20.269Z daily 0.9 https://cdn.brandfetch.io/BWAY/w/400/h/400?c=1idopYfmtR7ZKg8QMud BrainsWay, Inland Psychiatric Collaborate On Multi-System Deep TMS Deployment And Mental Health Research Initiatives BrainsWay Ltd. (NASDAQ & TASE: BWAY) has announced a strategic collaboration with Inland Psychiatric Medical Group (IPMG) to deploy multiple BrainsWay Deep TMS systems across IPMG clinics in Southern California. This partnership aims to enhance interventional psychiatry through various scientific and clinical research initiatives. The Deep TMS system, which is FDA-cleared for treating major depressive disorder, OCD, and smoking addiction, utilizes a patented coil design to stimulate underactive neural networks. https://openbell.ai/news/MSFT:1792409640028 2026-10-19T11:34:00.028Z daily 0.9 https://cdn.brandfetch.io/MSFT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bernstein Maintains Outperform on Microsoft, Raises Price Target to $662 Bernstein analyst Mark Moerdler has maintained an 'Outperform' rating on Microsoft (NASDAQ: MSFT) and increased the price target from $660 to $662. This adjustment reflects confidence in the company's performance and potential growth. https://openbell.ai/news/CRMD:1792409574120 2026-10-19T11:32:54.120Z daily 0.9 https://cdn.brandfetch.io/CRMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud CorMedix Therapeutics Says FDA Accepts sNDA Filing Seeking Approval Of REZZAYO For Prophylaxis Of Invasive Fungal Disease; PDUFA Target Action Date Set In Q1 2027 CorMedix Therapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for REZZAYO (rezafungin for injection) aimed at preventing invasive fungal disease. The application, submitted by CorMedix's partner Mundipharma, has been granted Priority Review with a PDUFA target action date set for Q1 2027. This sNDA is backed by positive results from the Phase III ReSPECT study, which assessed the drug's efficacy and safety in adults undergoing allogeneic HSCT. If approved, CorMedix plans to initiate promotional efforts in H2 2027. https://openbell.ai/news/CYTK:1792409484678 2026-10-19T11:31:24.678Z daily 0.9 https://cdn.brandfetch.io/CYTK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated (Nasdaq: CYTK) has received a Notice of Compliance from Health Canada, allowing the use of MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients classified as NYHA class II-III. MYQORZO is an oral medication that inhibits cardiac myosin motor activity, which helps reduce cardiac contractility and left ventricular outflow tract obstruction in patients with oHCM. https://openbell.ai/news/ASTS:1792409297711 2026-10-19T11:28:17.711Z daily 0.9 https://cdn.brandfetch.io/ASTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud AST SpaceMobile Welcomes European LoI Signed By Deutsche Telekom, Orange, Telefónica And Vodafone To Explore A Potential Joint Bid For Mobile Satellite Services Spectrum AST SpaceMobile has signed a Letter of Intent (LoI) with Deutsche Telekom, Orange, Telefónica, and Vodafone to explore a joint bid for mobile satellite services spectrum in Europe. This collaboration aims to enhance network integration and extend coverage to areas lacking reliable mobile connectivity, benefiting over 500 million mobile subscribers. AST SpaceMobile's BlueBird satellites, capable of peak download speeds of 98.9 Mbps, are designed to connect directly to standard smartphones, with future satellites expected to reach nearly 200 Mbps. The initiative supports a coordinated approach to spectrum access while maintaining data handling within European jurisdiction. https://openbell.ai/news/ASTS:1792409246176 2026-10-19T11:27:26.176Z daily 0.9 https://cdn.brandfetch.io/ASTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud AST SpaceMobile Welcomes European LoI Signed By Deutsche Telekom, Orange, Telefónica And Vodafone To Explore A Potential Joint Bid For Mobile Satellite Services AST SpaceMobile has signed a Letter of Intent (LoI) with Deutsche Telekom, Orange, Telefónica, and Vodafone to explore a potential joint bid for mobile satellite services in Europe. This collaboration aims to enhance network integration, customer experience, and coverage in areas lacking reliable mobile connectivity, while maintaining data control within European jurisdiction. AST SpaceMobile's BlueBird satellites, capable of connecting directly to standard smartphones, have demonstrated peak download speeds of 98.9 Mbps, with future satellites expected to reach nearly 200 Mbps, supporting various services for consumers and businesses. https://openbell.ai/news/MANE:1792409134798 2026-10-19T11:25:34.798Z daily 0.9 https://cdn.brandfetch.io/MANE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Maintains Buy on Veradermics, Raises Price Target to $172 Needham analyst Serge Belanger has maintained a Buy rating on Veradermics (NYSE: MANE) and increased the price target from $164 to $172. This adjustment reflects the analyst's positive outlook on the company's performance. https://openbell.ai/news/LEU:1792409004227 2026-10-19T11:23:24.227Z daily 0.9 https://cdn.brandfetch.io/LEU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Centrus Energy Acquires Supplier Westerman Holdings For ~$116M, Comprising ~$95M In Cash And $21M Of LEU Stock; Expects Deal To Be EPS Accretive In Year One Centrus Energy Corp. has acquired Westerman Holdings for approximately $116 million, funded by about $95 million in cash and $21 million in equity. The deal is expected to be accretive to adjusted earnings per share in the first year and aims to enhance Centrus' supply chain resilience and diversify its revenue base. Westerman, which will operate as a subsidiary under its own name, provides critical manufacturing capabilities and serves various industries, including nuclear and oil and gas. https://openbell.ai/news/LEU:1792408924688 2026-10-19T11:22:04.688Z daily 0.9 https://cdn.brandfetch.io/LEU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Centrus Energy Acquires Westerman Holdings For ~$116M, Funded Through Combination Of ~$95M Cash On Hand And $21M Of Equity Centrus Energy Corp. has acquired Westerman Holdings for approximately $116 million, financed with about $95 million in cash and $21 million in equity. This acquisition secures a key supplier of centrifuge components and diversifies Centrus' revenue by expanding into adjacent non-nuclear manufacturing markets. The transaction is anticipated to enhance growth through commercial and operational synergies, and is expected to be accretive to adjusted earnings per share in the first year. https://openbell.ai/news/TNXP:1792408464369 2026-10-19T11:14:24.369Z daily 0.9 https://cdn.brandfetch.io/TNXP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30 Tonix Pharmaceuticals will present findings on its drug TONMYA, which was approved by the FDA on August 15, 2025, and launched in the U.S. on November 17, 2025. The presentation, titled 'Cyclobenzaprine HCl Sublingual Reduces Fibromyalgia Impact on Physical Symptoms & Functional Ability,' will take place on October 27, 2026, at the World Congress on Pain. The poster session is scheduled for 3:15-4:45 p.m. ICT, and will be presented by Errol Gould, Ph.D., Senior Vice President of Medical Affairs at Tonix Medicines. https://openbell.ai/news/CGEM:1792408401069 2026-10-19T11:13:21.069Z daily 0.9 https://cdn.brandfetch.io/CGEM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Taiho Oncology and Cullinan Therapeutics Say Data From Cohort C Of Phase 2 REZILIENT2 Trial Of Zipalertinib For Locally Advanced Or Metastatic Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Or Uncommon EGFR Mutations and Active CNS Metastases Shows Intracranial Objective Response Rate Of 30.2% In 43 Evaluable Patients Taiho Oncology and Cullinan Therapeutics announced results from Cohort C of the Phase 2 REZILIENT2 trial for zipalertinib, targeting locally advanced or metastatic non-small cell lung cancer with EGFR mutations and active CNS metastases. The trial showed an intracranial objective response rate of 30.2% and a disease control rate of 72.1% among 43 evaluable patients, with a median duration of response of 9.7 months. The data will be presented at the ESMO Congress 2026 in Madrid, highlighting the potential of zipalertinib in this challenging patient population. https://openbell.ai/news/MANE:1792408400237 2026-10-19T11:13:20.237Z daily 0.9 https://cdn.brandfetch.io/MANE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Veradermics&#39; VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile Veradermics, Inc. (NYSE: MANE) announced that its oral minoxidil formulation VDPHL01 met all primary and secondary endpoints in a Phase 3 clinical trial, demonstrating significant hair count increases of 28.6 hairs/cm² for once-daily and 36.4 hairs/cm² for twice-daily dosing compared to 6.6 hairs/cm² for placebo at Month 6 (p<0.0001). Approximately 78.8% (QD) and 85.0% (BID) of participants reported visible improvements, with a favorable safety profile observed in over 1,000 participants across two studies. These results position VDPHL01 as a potential first FDA-approved non-hormonal oral treatment for the 50 million men with pattern hair loss in the U.S. https://openbell.ai/news/ATYR:1792408369507 2026-10-19T11:12:49.507Z daily 0.9 https://cdn.brandfetch.io/ATYR/w/400/h/400?c=1idopYfmtR7ZKg8QMud aTyr Pharma Enters Research Collaboration With Albert Einstein College Of Medicine To Develop And Test ATYR2810, Its Monoclonal Antibody That Targets The Neuropilin-2 Receptor aTyr Pharma has entered into a research collaboration with Albert Einstein College of Medicine to develop and test its monoclonal antibody, ATYR2810, which targets the neuropilin-2 receptor. The collaboration will be led by Dr. Bang H. Hoang, focusing on the role of NRP2 in pediatric bone cancers. ATYR2810 has shown anti-tumor effects in various preclinical models, including non-small cell lung cancer and glioblastoma, with findings presented at major scientific conferences. https://openbell.ai/news/INEO:1792408368982 2026-10-19T11:12:48.982Z daily 0.9 https://cdn.brandfetch.io/INEO/w/400/h/400?c=1idopYfmtR7ZKg8QMud INNEOVA Holdings Sees Preliminary Q1 FY2027 Revenue Above $1.3M, Up Over 25% QoQ and 350% YoY; Adjusted EBITDA Ranges From -$50K to $50K INNEOVA Holdings (NASDAQ: INEO) reported preliminary revenue for Q1 FY2027 exceeding $1.3 million, representing a quarterly growth of over 25% and an annual increase of 350%. The company's adjusted EBITDA is projected to range from -$50,000 to $50,000. https://openbell.ai/news/AZN:1792408256155 2026-10-19T11:10:56.155Z daily 0.9 https://cdn.brandfetch.io/AZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud AstraZeneca To Present 100+ Cancer Research Abstracts, Including Five Phase III Trials, At ESMO 2026 AstraZeneca will present over 100 cancer research abstracts, including data from five pivotal Phase III trials, at the ESMO Congress from October 23-27, 2026. Key highlights include the CLARITY-Gastric01 trial demonstrating significant overall survival benefits for Sone-Ve in CLDN18.2-positive gastric cancer, and the SAFFRON trial showing clinical benefits of combining TAGRISSO with savolitinib in EGFR-mutated lung cancer. Other trials will showcase innovative treatments for bladder and small cell lung cancers, emphasizing AstraZeneca's commitment to advancing cancer care. https://openbell.ai/news/UTHR:1792408191069 2026-10-19T11:09:51.069Z daily 0.9 https://cdn.brandfetch.io/UTHR/w/400/h/400?c=1idopYfmtR7ZKg8QMud The FDA Clears United Therapeutics&#39; Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease United Therapeutics Corporation (Nasdaq: UTHR) has received FDA clearance to proceed with the SUMMIT clinical trial of its investigational drug, treprostinil soft mist inhaler (SMI), for treating pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The phase 2 study will involve approximately 40 patients and assess the drug's safety, tolerability, and efficacy. If successful, United Therapeutics plans to initiate a phase 3 registration study in 2028, with potential for significant market expansion, as PH-COPD could affect five to ten times more patients than their current therapies. Treprostinil SMI is still in the investigational stage and not yet approved for any use. https://openbell.ai/news/GOGO:1792408190906 2026-10-19T11:09:50.906Z daily 0.9 https://cdn.brandfetch.io/GOGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gogo Outlines Long-Term Roadmap For Gogo Galileo, With Significant Improvements To Extend Value Of Customer Investments Through Mid-2030s Gogo has unveiled a long-term roadmap for its Gogo Galileo connectivity platform at NBAA-BACE 2026, aiming to enhance customer investment value through the mid-2030s. The plan includes substantial performance upgrades every 24 months, targeting download speeds five times and upload speeds ten times faster than current levels. Gogo emphasizes a reliable supply chain and minimal installation disruption to protect existing customer investments while expanding service availability globally. The roadmap is supported by Gogo's global presence and commitment to improved service management tools. https://openbell.ai/news/SLGN:1792408145522 2026-10-19T11:09:05.522Z daily 0.9 https://cdn.brandfetch.io/SLGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Silgan Holdings, Trivium Packaging To Combine Metal Packaging Businesses In $3.4B Transformational Deal Silgan Holdings Inc. is set to combine its Metal Containers segment and Food and Beverage Flat Cap Closures businesses with Trivium Packaging in a $3.4 billion all-cash deal, creating a new entity named Silgan Metal Containers and Closures (MCC). This transaction is expected to generate approximately $2.3 billion in cash proceeds for Silgan and will enhance its portfolio, driving at least 15% accretion to adjusted EPS and free cash flow, including expected synergies of $225 million. Silgan will retain a 60% ownership stake in the new partnership, while American Industrial Partners will hold the remaining 40% and contribute $1 billion in cash equity. https://openbell.ai/news/EQPT:1792408105386 2026-10-19T11:08:25.386Z daily 0.9 https://cdn.brandfetch.io/EQPT/w/400/h/400?c=1idopYfmtR7ZKg8QMud EquipmentShare.com Raises FY2026 Sales Guidance from $5.254B-$5.682B to $5.808B-$6.045B vs $5.580B Est EquipmentShare.com (NASDAQ: EQPT) has raised its fiscal year 2026 sales guidance from a range of $5.254 billion to $5.682 billion, now projecting between $5.808 billion and $6.045 billion. This updated forecast exceeds the previous market estimate of $5.580 billion. https://openbell.ai/news/SES:1792408090666 2026-10-19T11:08:10.666Z daily 0.9 https://cdn.brandfetch.io/SES/w/400/h/400?c=1idopYfmtR7ZKg8QMud SES AI Completes Production Ramp-Up At Its Drone Battery Plant In South Korea To Capacity 1M NDAA-Compliant Cells Per Year; Will Begin Expanding Plant To 3M Cells Annually By Q2 2027 SES AI Corporation has successfully ramped up its drone battery plant in Chungju, South Korea, to an annual production capacity of one million NDAA-compliant cells. Due to strong customer demand, the company plans to expand the facility's capacity to three million cells per year by Q2 2027. The plant, operational since 2021, focuses on high-silicon Li-ion and anode-free Li-Metal cells. https://openbell.ai/news/SMMT:1792408072232 2026-10-19T11:07:52.232Z daily 0.9 https://cdn.brandfetch.io/SMMT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Summit Therapeutics Announced Opening Of Global Phase II SMT112-216 Trial Of Ivonescimab Alone Or Combined With Cadonilimab Or Ipilimumab In Previously Untreated Advanced Clear Cell Renal Cell Carcinoma, openbell Financial News https://openbell.ai/news/GLBE:1792408042523 2026-10-19T11:07:22.523Z daily 0.9 https://cdn.brandfetch.io/GLBE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Upgrades Global E Online to Overweight, Raises Price Target to $50 Morgan Stanley analyst James Faucette has upgraded Global E Online (NASDAQ: GLBE) from Equal-Weight to Overweight. The price target for the stock has been raised from $46 to $50. https://openbell.ai/news/EYPT:1792408040163 2026-10-19T11:07:20.163Z daily 0.9 https://cdn.brandfetch.io/EYPT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint Eyepoint Pharmaceuticals announced that the LUCIA Phase 3 trial for its Duravyu (Vorolanib Intravitreal Insert) for wet age-related macular degeneration did not meet its primary endpoint of statistical non-inferiority compared to the on-label aflibercept control. However, the trial achieved key secondary endpoints, including a 38% reduction in treatment burden and a favorable safety profile. The company is also on track with its DME program, expecting pivotal Phase 3 topline data from two identical clinical trials in Q4 2027. https://openbell.ai/news/TGEM:1792408031781 2026-10-19T11:07:11.781Z daily 0.9 https://cdn.brandfetch.io/TGEM/w/400/h/400?c=1idopYfmtR7ZKg8QMud TriGemX Bio To Go Public Through Merger With TCGX Acquisition, Plans Nasdaq Listing Under TGEM; Upon Closing, Combined Company Expected to Receive ~$246M Of Gross Proceeds TriGemX Bio is set to go public through a merger with TCGX Acquisition Corp., with plans to list on Nasdaq under the ticker symbol 'TGEM'. The transaction is expected to generate approximately $246 million in gross proceeds, which includes $86 million from TCGX's trust account and a $160 million private investment in public equity (PIPE) financing. The PIPE financing will involve shares sold at $10.00 each to various prominent healthcare investors. https://openbell.ai/news/ANNX:1792407974704 2026-10-19T11:06:14.704Z daily 0.9 https://cdn.brandfetch.io/ANNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright &amp; Co. Maintains Buy on Annexon, Raises Price Target to $25 HC Wainwright & Co. analyst Ananda Ghosh has maintained a Buy rating on Annexon (NASDAQ: ANNX) and raised the price target from $14 to $25. This adjustment reflects a positive outlook for the company's stock performance. https://openbell.ai/news/IRON:1792407964599 2026-10-19T11:06:04.599Z daily 0.9 https://cdn.brandfetch.io/IRON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Disc Medicine Announced Pivotal Phase 3 APOLLO Trial Of Bitopertin In EPP Met All Co-Primary, Secondary Endpoints openbell Financial News https://openbell.ai/news/AMP:1792407920980 2026-10-19T11:05:20.980Z daily 0.9 https://cdn.brandfetch.io/AMP/w/400/h/400?c=1idopYfmtR7ZKg8QMud B of A Securities Downgrades Ameriprise Financial to Underperform, Lowers Price Target to $445 B of A Securities has downgraded Ameriprise Financial (NYSE: AMP) from a Buy rating to Underperform. The price target for the stock has been reduced from $570 to $445. https://openbell.ai/news/XNDU:1792407917677 2026-10-19T11:05:17.677Z daily 0.9 https://cdn.brandfetch.io/XNDU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Xanadu Quantum Technologies Receives Provisional Approval For Project Funding Of Up To $10M Under DARPA&#39;s Quantum Benchmarking Initiative Xanadu Quantum Technologies has received provisional approval for project funding of up to $10 million under DARPA's Quantum Benchmarking Initiative (QBI). This one-year contract extension will support the company's R&D efforts, focusing on advancing its photonic quantum computing architecture, which offers advantages such as minimal cooling requirements and fast clock speeds. Xanadu aims to utilize the funding to accelerate critical components of its R&D roadmap while providing regular progress reports to DARPA for evaluation. https://openbell.ai/news/SEED:1792407891061 2026-10-19T11:04:51.061Z daily 0.9 https://cdn.brandfetch.io/SEED/w/400/h/400?c=1idopYfmtR7ZKg8QMud Origin Agritech Announced Exclusive Provincial Corn Seed Distribution Agreement With Jinan Jingkun Trading Across China&#39;s Shandong Province, Receiving Initial RMB 2.9M Payment Toward Prepayment Obligations openbell Financial News https://openbell.ai/news/MRKR:1792407878209 2026-10-19T11:04:38.209Z daily 0.9 https://cdn.brandfetch.io/MRKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer Marker Therapeutics, Inc. (NASDAQ: MRKR) has secured $2.6 million from the FDA through its Orphan Products Clinical Trials grants program to support a Phase 1 clinical study of its lead investigational MAR-T cell therapy, MT-601, aimed at treating locally advanced unresectable pancreatic cancer. This funding is part of a competitive initiative to promote research for rare diseases, with only six out of 66 applications receiving support in fiscal year 2026. https://openbell.ai/news/PBLS:1792407769118 2026-10-19T11:02:49.118Z daily 0.9 https://cdn.brandfetch.io/PBLS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026 Parabilis Medicines (NASDAQ: PBLS) will present updated clinical data for zolucatetide in patients with desmoid tumors at the ESMO Congress 2026, scheduled for October 23-27, 2026, in Madrid, Spain. The presentation will include data from the ongoing Phase 1/2 trial, focusing on dose optimization to inform the upcoming Phase 3 registrational trial. Zolucatetide has received Fast Track and Orphan Drug Designations from the FDA for treating desmoid tumors. https://openbell.ai/news/PLTR:1792407681884 2026-10-19T11:01:21.884Z daily 0.9 https://cdn.brandfetch.io/PLTR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Knox Systems Announces New Partnership With Palantir Technologies To Accelerate Secure AI Deployment In FedRAMP And IL5 Environments Knox Systems has announced a new partnership with Palantir Technologies Inc. (NASDAQ: PLTR) to enhance secure AI deployment in FedRAMP and IL5 environments for U.S. Government and Department of War clients. This collaboration aims to leverage Knox's rapid FedRAMP authorization process, which can be completed in 90 days or less, alongside Palantir's established infrastructure for federal software deployment. The partnership is expected to streamline access for commercial innovators to government contracts, benefiting both companies' capabilities in serving critical mission sets. https://openbell.ai/news/VAI:1792407582621 2026-10-19T10:59:42.621Z daily 0.9 https://cdn.brandfetch.io/VAI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Valor Energy To Acquire 18MW Operational Computing Center In Ohio For $3.6M Valor Energy Inc. (NASDAQ: VAI) has announced an agreement to acquire an 18MW operational computing center in Youngstown, Ohio, for $3.6 million. The acquisition is subject to due diligence and other closing conditions, with a closing timeline expected within 90 business days. The facility, which spans approximately 30,888 square feet, will be converted into an AI data center, although additional construction and permitting work will be required. Valor Energy aims to expedite its AI computing capacity deployment by acquiring an operational site rather than undeveloped land. https://openbell.ai/news/ANIP:1792407447096 2026-10-19T10:57:27.096Z daily 0.9 https://cdn.brandfetch.io/ANIP/w/400/h/400?c=1idopYfmtR7ZKg8QMud ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug Cymbalta ANI Pharmaceuticals, Inc. has launched Duloxetine Delayed-Release Capsules in 20, 30, and 60 mg, which are the generic version of Cymbalta. The U.S. annual sales for Duloxetine are approximately $247 million, according to August 2026 moving annual total (MAT) IQVIA data. https://openbell.ai/news/IRON:1792407337971 2026-10-19T10:55:37.971Z daily 0.9 https://cdn.brandfetch.io/IRON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trading Halt: Halted at 6:55:37 a.m. ET - Trading Halt: Halt News Pending openbell Financial News https://openbell.ai/news/EYPT:1792407300543 2026-10-19T10:55:00.543Z daily 0.9 https://cdn.brandfetch.io/EYPT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending openbell Financial News https://openbell.ai/news/RCAT:1792407152485 2026-10-19T10:52:32.485Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Red-CatMunich--Bavaria--Germany---March-.jpg?width=250&height=187 Red Cat Eyes Global Defense Market Expansion Through Steyr Motors Takeover Red Cat Holdings Inc. (NASDAQ: RCAT) has proposed an all-cash offer to acquire Austrian engine manufacturer Steyr Motors AG for 39 euros per share, representing a 28.9% premium over Steyr's closing share price on October 16. The acquisition aims to enhance Red Cat's autonomous maritime defense business by integrating Steyr's specialized marine engines with its unmanned surface vessels. The deal is supported by Steyr's major shareholder, B&C Holding Österreich GmbH, and requires regulatory approvals in multiple countries. Red Cat reported $325.6 million in cash as of June 30, 2026, and its shares rose 8.05% to $5.09 in premarket trading following the announcement. https://openbell.ai/news/VFS:1792407149692 2026-10-19T10:52:29.692Z daily 0.9 https://cdn.brandfetch.io/VFS/w/400/h/400?c=1idopYfmtR7ZKg8QMud VinFast Q2 2026 EV Deliveries Rose 96% YoY And 20% QoQ To 70,085 Vehicles, openbell Financial News https://openbell.ai/news/KKR:1792407135952 2026-10-19T10:52:15.952Z daily 0.9 https://cdn.brandfetch.io/KKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud KKR To Sell Infinity Transportation To Ares Infrastructure Equity And Ares Insurance Solutions Funds For Enterprise Value Of ~$2.9B KKR & Co. Inc. has entered into a definitive agreement to sell Infinity Transportation, a railcar and intermodal equipment lessor, to Ares Infrastructure Equity and Ares Insurance Solutions funds for an enterprise value of approximately $2.9 billion. The transaction is expected to close in the first quarter of 2027, pending customary closing conditions and regulatory approvals. Ares plans to utilize its infrastructure investing capabilities to support Infinity's management team and enhance fleet growth. https://openbell.ai/news/WIX:1792406861834 2026-10-19T10:47:41.834Z daily 0.9 https://cdn.brandfetch.io/WIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Maintains Overweight on Wix.com, Raises Price Target to $90 Cantor Fitzgerald analyst Deepak Mathivanan has maintained an Overweight rating on Wix.com (NASDAQ: WIX) and raised the price target from $80 to $90. This adjustment reflects a positive outlook for the company's stock performance. https://openbell.ai/news/SLGN:1792406533351 2026-10-19T10:42:13.351Z daily 0.9 https://cdn.brandfetch.io/SLGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud &#39;Silgan Nears $3.4 Billion Purchase of Trivium Packaging&#39; - Bloomberg Silgan Holdings is nearing a $3.4 billion acquisition of Trivium Packaging, which is expected to enhance its product offerings in the packaging sector. This strategic move aims to strengthen Silgan's market position and expand its capabilities. The deal reflects Silgan's ongoing efforts to grow through acquisitions in the competitive packaging industry. https://openbell.ai/news/UBER:1792406459609 2026-10-19T10:40:59.609Z daily 0.9 https://cdn.brandfetch.io/UBER/w/400/h/400?c=1idopYfmtR7ZKg8QMud &#39;Uber Wins Bid to Dismiss £250 Million Black Cab Driver Suit&#39; - Bloomberg Uber has successfully dismissed a £250 million lawsuit filed by black cab drivers in the UK. The lawsuit alleged that Uber's operations were unfairly impacting the traditional taxi industry. This legal victory may have positive implications for Uber's financial standing and market position in the UK. https://openbell.ai/news/DOW:1792406347070 2026-10-19T10:39:07.070Z daily 0.9 https://cdn.brandfetch.io/DOW/w/400/h/400?c=1idopYfmtR7ZKg8QMud B of A Securities Upgrades Dow to Neutral, Raises Price Target to $31 B of A Securities has upgraded Dow (NYSE: DOW) from Underperform to Neutral, as announced by analyst Matthew DeYoe. Additionally, the price target for Dow's stock has been increased from $29 to $31. https://openbell.ai/news/KKR:1792406241312 2026-10-19T10:37:21.312Z daily 0.9 https://cdn.brandfetch.io/KKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud &#39;KKR to Sell Railcar-Leasing Company Infinity to Ares for $2.9 Billion&#39; - WSJ KKR is set to sell its railcar-leasing company, Infinity, to Ares for $2.9 billion. This transaction marks a significant move in the railcar leasing market and reflects KKR's strategic focus on optimizing its portfolio. The sale is expected to impact KKR's financial standing, although specific details on revenue or profit from the sale were not disclosed. https://openbell.ai/news/LCII:1792406232387 2026-10-19T10:37:12.387Z daily 0.9 https://cdn.brandfetch.io/LCII/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Downgrades LCI Industries to Hold, Lowers Price Target to $80 Stifel analyst Nathan Jones has downgraded LCI Industries (NYSE: LCII) from a 'Buy' to 'Hold' rating. Additionally, the price target for the stock has been reduced from $130 to $80. https://openbell.ai/news/INFY:1792406132372 2026-10-19T10:35:32.372Z daily 0.9 https://cdn.brandfetch.io/INFY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Infosys Expands Collaboration With Truist To Support Bank&#39;s Continued Build-Out Of Its AI-First Global Capability Center In Hyderabad Infosys (NSE: INFY, BSE: INFY, NYSE: INFY) has expanded its collaboration with Truist, a major US financial services firm, to support the development of an AI-first Global Capability Center in Hyderabad. This partnership aims to consolidate multiple supplier relationships into a unified operating model, leveraging Infosys's expertise in financial services and AI. The initiative will also see the onboarding of over 1,000 new employees, marking a significant milestone in the growth of the center. https://openbell.ai/news/RXRX:1792406071858 2026-10-19T10:34:31.858Z daily 0.9 https://cdn.brandfetch.io/RXRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals (NASDAQ: RXRX) and has maintained a price target of $8 for the stock. https://openbell.ai/news/AOS:1792406042790 2026-10-19T10:34:02.790Z daily 0.9 https://cdn.brandfetch.io/AOS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Downgrades A.O. Smith to Hold, Lowers Price Target to $59 Stifel analyst Nathan Jones has downgraded A.O. Smith (NYSE: AOS) from a Buy rating to Hold. Additionally, the price target for the stock has been reduced from $70 to $59. https://openbell.ai/news/USAS:1792406021123 2026-10-19T10:33:41.123Z daily 0.9 https://cdn.brandfetch.io/USAS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Americas Gold And Silver Reports Consolidated Silver Production Of 800,458 Ounces For Q3 2026; Sells 860,850 Ounces Of Silver In Q3 Americas Gold and Silver Corporation reported a record consolidated silver production of 800,458 ounces for Q3 2026 and sold 860,850 ounces of silver during the same period. Additionally, the company produced 964,551 pounds of lead (with sales of 1,417,512 pounds), 918,456 pounds of copper (sales of 928,967 pounds), and 101,011 pounds of antimony (sales of 121,691 pounds). https://openbell.ai/news/SLGL:1792405983162 2026-10-19T10:33:03.162Z daily 0.9 https://cdn.brandfetch.io/SLGL/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright &amp; Co. Reiterates Buy on Sol-Gel Technologies, Maintains $110 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Sol-Gel Technologies (NASDAQ: SLGL) and maintained a price target of $110. This endorsement reflects the firm's confidence in the company's potential for growth.